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In Brief
UCP1 was recently proposed as being
dispensable for anti-obesity and anti-
diabetic actions of FGF21. Kwon et al.
show that FGF21 lowers body weight
without UCP1. However, FGF21-
mediated improvements in glucose
clearance require UCP1 and correlate
with increased temperature, pointing to
thermogenesis as the mechanism of
increased glucose disposal.
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Fibroblast growth factor 21 (FGF21)-mediated
weight loss and improvements in glucose meta-
bolism correlate with increased uncoupling protein
1 (Ucp1) levels in adipose tissues, suggesting that
UCP1-dependent thermogenesis may drive FGF21
action. It was reported that FGF21 is equally effective
at reducing body weight and improving glucose ho-
meostasis without UCP1. We find while FGF21 can
lower body weight in both wild-type and Ucp1
knockout mice, rapid clearance of glucose by
FGF21 is defective in the absence of UCP1. Further-
more, in obese wild-type mice there is a fall in brown
adipose tissue (BAT) temperature during glucose
excursion, and FGF21 improves glucose clearance
while preventing the fall in BAT temperature. In
Ucp1 knockout mice, the fall in BAT temperature dur-
ing glucose excursion and FGF21-mediated changes
in BAT temperature are lost. We conclude FGF21-
mediated improvements in clearance of a glucose
challenge require UCP1 and evoke UCP1-dependent
thermogenesis as a method to increase glucose
disposal.INTRODUCTION
Fibroblast growth factor 21 (FGF21) has attributes of a promising
therapeutic for obesity and type 2 diabetes. FGF21 delivery to ro-
dent models of obesity and diabetes reduces body weight and
improves glucose metabolism (Coskun et al., 2008; Kharitonen-
kov et al., 2005; Xu et al., 2009a, 2009b). These actions of FGF21
appear to correlate with increased Ucp1 mRNA levels and pro-
tein immunoreactivity in adipose tissues (Coskun et al., 2008;
Emanuelli et al., 2014; Fisher et al., 2012). Given that UCP1
can dissipate the mitochondrial proton gradient, thereby re-
leasing energy derived from mitochondrial substrate oxidation
as heat, FGF21-mediated increases in UCP1 levels have led to
a widespread speculation that UCP1-dependent thermogenesis
may drive the therapeutic actions of FGF21. Surprisingly, it was
reported recently that UCP1 is not required for FGF21-mediatedCell Repreduction in body weight or improvements in glucose homeo-
stasis (Samms et al., 2015; Ve´niant et al., 2015).
We also tested the ability of FGF21 to lower body weight and
improve glucose homeostasis in mice with a genetic ablation of
UCP1 to determine whether UCP1 is required for these thera-
peutic actions of FGF21. In agreement with these two recent
publications, we found that FGF21 can lower body weight in
the absence of UCP1. However, in contrast to previous reports,
we have found, in three independent cohorts of mice with two
distinct methods of FGF21 administration, that FGF21-mediated
improvements in glucose clearance are lost in the absence of
UCP1. Moreover, FGF21 increases thermogenesis during
glucose clearance, which is lost in the absence of UCP1. There-
fore, FGF21 can improve many metabolic parameters including
body weight in the absence of UCP1; however, FGF21 requires
UCP1 to improve glucose clearance, likely involving increased
UCP1-dependent thermogenesis.RESULTS
UCP1 Is Not Required for FGF21-Mediated Lowering of
Body Weight in Diet-Induced Obese Mice
To determine whether FGF21 confers its anti-obesity and anti-
diabetic effects through UCP1, we examined FGF21 therapeutic
efficacy in the complete absence of UCP1. We also evaluated
the effectiveness of FGF21 at elevated levels that were sustained
for many months, beyond the few days or weeks that have been
typically examined. Mice with a genetic deletion of Ucp1
(Ucp1/) and age-matched wild-type controls (Ucp1+/+) were
fed a high-fat diet (HFD) for 9 weeks. To determine the extent
to which FGF21 normalizes metabolic parameters in HFD-fed
mice, we also included low-fat diet (LFD)-fed Ucp1+/+ and
Ucp1/ mice as controls (n = 3–6 for all groups). In both geno-
types, HFD caused comparable excessweight gain compared to
LFD controls (Figure S1). HFD-fed mice were then either given
plasmid encoding human FGF21 or empty (vehicle) plasmid,
delivered via hydrodynamic transfer. Plasma human FGF21
levels were below the detection limit (<15 pg/ml) in LFD and
HFD vehicle mice for both genotypes, and hydrodynamic
FGF21 delivery increased plasma human FGF21 to pharmaco-
logical levels by day 3 in Ucp1+/+ and Ucp1/ mice (42,619 ±
7,762 pg/ml and 51,110 ± 12,716 pg/ml, respectively; Figures
1A and 1B). The levels remained elevated throughout the studyorts 13, 1521–1527, November 24, 2015 ª2015 The Authors 1521
Figure 1. Genetic Ablation of UCP1 Does Not Block FGF21-Mediated Lowering of Body Weight
Ucp1+/+ and Ucp1/ mice were fed either a low-fat diet (LFD) or rendered obese with a high-fat diet (HFD).
(A–D) On day 0, empty plasmid (vehicle) or plasmid encoding human FGF21 was administered to HFD-fed Ucp1+/+ (filled circles, left) and Ucp1/ mice (open
circles, right) via hydrodynamic delivery. Plasma human FGF21 (hFGF21) levels (A and B) and percentage change in body weights from day of plasmid injection
(C and D) were tracked throughout the study and data are shown for individual animals. Plasma hFGF21 levels in all LFD and vehicle mice were undetectable and
set to the lowest detection limit of assay (<15 pg/ml). See Figure S1 for absolute body weights. Statistical analyses were performed by two-way ANOVA on
average values for each group (*p < 0.05 HFD-vehicle versus HFD-FGF21 for both genotypes).
(E–L) On day 47, fat mass (E and I), lean mass (F and J), bone mineral density (BMD, G and K), and body lengths (H and L) were measured. (E)–(L) are minimum to
maximumwhisker plots and statistical analysis was performed by one-way ANOVA for both genotypes (*p < 0.05 HFD-vehicle versus HFD-FGF21, yp < 0.05 LFD
versus HFD-vehicle, and zp < 0.05 LFD versus HFD-FGF21; NS, not significant; n = 3–6).(11,971 ± 1,450 pg/ml and 15,862 ± 4,913 pg/ml, respectively,
on day 95), thus allowing us to assess the long-term therapeutic
efficacy of FGF21. These levels of plasma human FGF21 are
comparable to the levels achieved by delivering recombinant hu-
man FGF21 at a dose of 0.1–1 mg/kg/day via mini-osmotic
pumps (Coskun et al., 2008).
FGF21 treatment in wild-type Ucp1+/+ mice reduced body
weight by 14.5% ± 2.4% on day 10 and by 19.6% ± 8.7% on
day 30, whereas body weight increased in vehicle control
Ucp1+/+ mice by 4.1% ± 0.4% on day 10 and 9.4% ± 1.4% on
day 30 (Figure 1C). Consistent with prior reports (Samms et al.,
2015; Ve´niant et al., 2015), FGF21 was equally as effective at
reducing body weight in Ucp1 knockout mice as in wild-type
mice; FGF21 treatment of Ucp1/ mice reduced body weight
by 14.4% ± 2.0% on day 10 and by 19.5% ± 5.2% on day 30,
whereas body weight increased in vehicle control Ucp1/1522 Cell Reports 13, 1521–1527, November 24, 2015 ª2015 The Aumice by 1.4% ± 1.0%on day 10 and 4.8% ± 1.1%on day 30 (Fig-
ure 1D). In Ucp1+/+ mice, FGF21 significantly lowered fat mass
compared to vehicle (Figure 1E), and there was a trend toward
decreased lean mass (p = 0.28; Figure 1F). Similarly, FGF21-
treated Ucp1/mice had significantly lower fat mass (Figure 1I)
and lean mass compared to vehicle controls (Figure 1J), which is
consistent with the findings of Samms et al. (2015).
It has been reported that life-long overexpression of FGF21
and pharmacological FGF21 treatment leads to decreased
bone mineral density (BMD) and bone loss (Wei et al., 2012);
however, we did not observe a difference in whole-body BMD
or body length between vehicle and FGF21 groups in both geno-
types (Figures 1G, 1H, 1K, and 1L). While whole-body BMD was
not significantly altered by chronic FGF21 overexpression in
our studies, it is possible there were site-specific changes in
BMD we did not detect. Interestingly, despite maintenance ofthors
Figure 2. FGF21-Mediated Improvement in Glucose Clearance Is Lost in the Absence of UCP1
(A and B) In vehicle or FGF21-treated Ucp1+/+ (filled circles, left) and Ucp1/ mice (open circles, right), 4-hr-fasted blood glucose levels were tracked.
(C–H) Oral glucose tolerance tests (OGTTs) were performed on day 6 (C and F) and day 22 (D and G). OGTT data are reported as the change (D) in blood glucose
levels from time 0 and the area under the curve (AUC) for OGTT curves (E and H). (A) and (B) are time 0 blood glucose levels for (C)–(F).
(I–K) In cohort 2, HFD-fedUcp1+/+ andUcp1/mice were injected with vehicle or plasmids encoding human FGF21. An OGTT was performed on day 7 in vehicle
and FGF21-treated Ucp1+/+ (filled circles, I) and Ucp1/ mice (open circles, J), and AUC was calculated (K). Basal blood glucose levels were as follows: 9.7 ±
0.6 mM, Ucp1+/+ HFD-vehicle mice; 8.1 ± 1.0 mM, Ucp1+/+ HFD-FGF21 mice; 10.2 ± 0.3 mM, Ucp1/ HFD-vehicle mice; and 9.3 ± 0.6 mM, Ucp1/
HFD-FGF21 mice.
(L–N) In cohort 3, HFD-fed Ucp1+/+ and Ucp1/ mice received adenovirus expressing b-galactosidase (Ad-b-gal) or human FGF21 (Ad-FGF21). On day 2, an
OGTTwas performed in allUcp1+/+ (filled circles, L) andUcp1/mice (open circles, M), and AUCwas calculated (N). Basal absolute blood glucose levels were as
follows: 7.7 ± 0.8mM,Ucp1+/+ LFDmice; 11.3 ± 1.2mM,Ucp1+/+ HFD-Ad-b-gal mice; 11.0 ± 0.5mM,Ucp1+/+ HFD-Ad-FGF21mice; 7.9 ± 0.4mM,Ucp1/ LFD
mice; 12.7 ± 0.7 mM, Ucp1/ HFD-Ad-b-gal mice; and 13.4 ± 1.1 mM, Ucp1/ HFD-Ad-FGF21 mice. Line graphs are mean ± SEM and AUC graphs
are minimum to maximum whisker plots. Statistical analysis was performed by one-way (AUC graphs) and two-way ANOVAs (all line graphs) for both genotypes
(*p < 0.05 HFD-vehicle versus HFD-FGF21, yp < 0.05 LFD versus HFD-vehicle for cohorts 1 and 3, and zp < 0.05 LFD versus HFD-FGF21 for cohorts 1 and 3;
n = 3–6 for cohort 1, n = 4–5 for cohort 2, and n = 4–6 for cohort 3).human plasma FGF21 immunoreactivity at pharmacological
levels, body weight-reducing effects of FGF21 therapy waned
in Ucp1+/+ mice between days 22 and 30, and body weights re-
turned to near pre-treatment values in most mice by day 95 (Fig-
ures 1C and 1D), suggesting decreased therapeutic efficacy. The
decreased therapeutic efficacy also was observed when mouse
FGF21was overexpressed inwild-typemice, suggesting that the
diminishing body weight-reducing actions of FGF21 do not sim-
ply result from a neutralization response specific to the foreign
human version of FGF21 in mice (Figure S2). Collectively, these
data suggest that FGF21 can lower body weight independent
of UCP1, but the anti-obesity effects of FGF21 therapy may
eventually wane with chronic delivery.Cell RepFGF21-Mediated Normalization of Fasting Blood
Glucose Levels Does Not Require UCP1
We postulated that the beneficial effects of FGF21 therapy on
glucose metabolism also would be UCP1 independent. By day
10, 4-hr-fasted blood glucose levels were normalized in
FGF21-treated Ucp1+/+ mice compared to vehicle (Figure 2A),
reaching LFD lean control levels. Similarly, FGF21 normalized
4-hr-fasted blood glucose levels in Ucp1/ mice compared to
vehicle by day 14 (Figure 2B), which is consistent with previous
reports (Samms et al., 2015; Ve´niant et al., 2015), although these
authors did not specify whether blood glucose levels were
measured in the fasted or fed state. Fasting hyperglycemia
induced by HFD feeding began to spontaneously improveorts 13, 1521–1527, November 24, 2015 ª2015 The Authors 1523
beyond days 57 and 80 in HFD vehicle Ucp1+/+ and Ucp1/
groups, respectively, such that we were unable to assess
FGF21-mediated improvements in fasted blood glucose levels
beyond these time points. Nevertheless, FGF21 normalized
4-hr-fasted blood glucose levels in both Ucp1+/+ and Ucp1/
mice between days 14 and 57, suggesting that FGF21-
mediated normalization of fasting blood glucose levels is UCP1
independent.
UCP1 Is Required for FGF21-Mediated Improvements in
Glucose Clearance in Diet-Induced Obese Mice
Next, we assessed whether FGF21 could improve clearance of a
glucose load independent of UCP1 by performing glucose toler-
ance tests. FGF21-treated Ucp1+/+ mice had significantly
improved oral glucose tolerance on day 6 compared to vehicle
(area under the curve [AUC] 446 ± 63 versus 1,253 ± 31,
p < 0.0001), even beyond that of LFD-fed lean Ucp1+/+ mice
(AUC 713.4 ± 61, p < 0.05; Figures 2C and 2E). Surprisingly,
FGF21 treatment did not improve glucose tolerance relative to
vehicle in Ucp1/ mice (AUC 2,174 ± 37 versus 1,892 ± 174,
p = 0.32; Figures 2F and 2H). Similarly, on day 22, FGF21 signif-
icantly improved glucose clearance compared to controls in
Ucp1+/+ mice, but not in Ucp1/ mice (Figures 2D, 2E, 2G,
and 2H).
We then repeated our glucose tolerance tests in two additional
independent cohorts of diet-induced obese Ucp1+/+ and
Ucp1/ mice using two distinct methods of FGF21 delivery
(herein referred to as cohorts 2 and 3). For cohort 2, we again
overexpressed FGF21 by hydrodynamic delivery. In both
Ucp1+/+ and Ucp1/ mice, plasma human FGF21 reached
pharmacological levels (21,942 ± 7,144 pg/ml and 23,995 ±
6,121 pg/ml, respectively, on day 14), which led to comparable
weight loss (8.9% ± 2.4% and 8.2% ± 2.8%, respectively,
on day 14; n = 4–5 for all groups in cohort 2). FGF21 significantly
improved clearance of glucose in Ucp1+/+ mice, but not in
Ucp1/ mice, on day 7 when glucose was delivered orally (Fig-
ures 2I–2K). On day 14, we tested whether FGF21-mediated
clearance of glucose also would be lost in the absence of
UCP1 when glucose was delivered via intraperitoneal (i.p.) injec-
tions (Figure S3). At all time points after glucose injection, there
was at least one animal with blood glucose levels beyond the
limit of detection (>33.3 mM), preventing us from performing sta-
tistical analysis. However, at both 60 and 90min after glucose in-
jection, FGF21-treatedUcp1+/+ mice tended to have lower blood
glucose levels compared to vehicle, and this trend was not
observed in Ucp1/ mice at these time points.
For cohort 3, we delivered human FGF21 by administration of
an adenovirus (Ad-FGF21) or a control adenovirus expressing
b-galactosidase (Ad-b-gal). Ad-FGF21 modestly increased
plasma human FGF21 levels in both Ucp1+/+ and Ucp1/
mice (1,354 ± 176 pg/ml and 1,490 ± 111 pg/ml, respectively,
on day 10; Figures S4A and S4C) and caused comparable weight
loss (6.3% ± 1.0% and 7.8% ± 1.6%, respectively, on day
10; Figures S4B and S4D; n = 4–6 for all groups in cohort 3).
To separate direct FGF21 action on glucose clearance from
the secondary benefits of weight loss, we performed a glucose
tolerance test on day 2 when plasma human FGF21 levels
were elevated but there were no significant changes in body1524 Cell Reports 13, 1521–1527, November 24, 2015 ª2015 The Auweight in both genotypes compared to the Ad-b-gal groups (Fig-
ures S4A–S4D). Ad-FGF21 treatment significantly improved
glucose clearance inUcp1+/+ mice relative to the Ad-b-gal group
(Figures 2L and 2N), which indicates that FGF21-mediated
improvements in glucose clearance are at least partially inde-
pendent of actions on body weight, as previously reported (Xu
et al., 2009a). In contrast, Ad-FGF21 treatment did not improve
glucose clearance in Ucp1/ mice compared to the Ad-b-gal
group (Figures 2M and 2N). Therefore, in all three independent
cohorts of Ucp1+/+ and Ucp1/ mice, whether elevated by hy-
drodynamic or adenoviral delivery of FGF21, FGF21 significantly
improved glucose clearance compared to controls in Ucp1+/+
mice, but not in Ucp1/ mice. These data suggest that FGF21
requires UCP1 to promote glucose clearance.
Glucose-Stimulated Insulin Levels and Insulin
Sensitivity Are Comparable between Ucp1+/+ and
Ucp1/ Mice
Observing the inability of FGF21 to improve glucose clearance in
Ucp1/ mice, we assessed whether these mice may have de-
fects in glucose-stimulated insulin levels or insulin action. Before
and during glucose load on day 6, vehicle Ucp1+/+ and Ucp1/
mice were hyperinsulinemic compared to FGF21-treated
Ucp1+/+ and Ucp1/ mice (Figures 3A–3D). Basal insulin levels
were comparable between FGF21-treated Ucp1+/+ andUcp1/
mice (1.3 ± 0.4 ng/ml and 2.0 ± 0.9 ng/ml, respectively; Figures
3A and 3C), and, at 15 min post-glucose, plasma insulin levels
tended to increase 2- to 3-fold in both groups, although the
response in the FGF21-treated Ucp1+/+ group did not reach sta-
tistical significance (p = 0.24). During the glucose tolerance test
on day 22, basal insulin levels in FGF21-treated Ucp1+/+ and
Ucp1/ mice were again comparable (1.4 ± 0.3 ng/ml and
1.0 ± 0.2 ng/ml, respectively; Figures 3B and 3D), again with
similar 2- to 3-fold increases in plasma insulin levels at
15 min post-glucose. On day 14, FGF21-treated Ucp1+/+ and
Ucp1/ mice had improved insulin sensitivity compared to
vehicle, and the degree of blood glucose lowering by insulin
was similar between FGF21-treated Ucp1+/+ and Ucp1/
mice (Figures 3E and 3F). Thus, despite differences in glucose-
lowering action of FGF21 inUcp1+/+ andUcp1/mice, basal in-
sulin levels, glucose-stimulated insulin secretion, and insulin
sensitivity are comparable.
Glucose Excursions in FGF21-Treated Wild-Type Mice
Correlate with Increased BAT and Surface Body
Temperatures
To directly assess whether UCP1-dependent thermogenesis
may contribute to FGF21-mediated increases in glucose clear-
ance, we tracked changes in the temperature of the body surface
and brown adipose tissue (BAT) region during glucose excursion
using infrared thermal imaging and by surgical implantation of
temperature transponders in the interscapular region, respec-
tively. Interestingly, in vehicle Ucp1+/+ mice (untreated and
obese), glucose excursion (Figure 4A) correlated with a fall in
BAT temperature (Figure 4B) and a substantial reduction in sur-
face body heat (Figure 4G). These data highlight the potential
role of defective BAT thermogenesis in glucose intolerance.
Remarkably, FGF21 treatment improved glucose excursionsthors
Figure 3. FGF21-Treated Ucp1+/+ and
Ucp1/ Mice Have Comparable Insulin
Levels and Insulin Sensitivity
(A–D) In vehicle or FGF21-treated Ucp1+/+ (closed
circles, left) andUcp1/mice (open circles, right),
plasma insulin levels were measured during
OGTTs (glucose-stimulated insulin secretion,
GSIS) on day 6 (A and C) and day 22 (B and D).
(E and F) In the same mice (cohort 1, also corre-
sponding to Figures 1 and 2A–2H), an insulin
tolerance test (ITT) was performed on day 14
(E and F). Data are shown as mean ± SEM and
statistical analysis was performed by two-way
ANOVA for both genotypes (*p < 0.05 HFD-vehicle
versus HFD-FGF21, yp < 0.05 LFD versus HFD
vehicle, and #p < 0.05 indicated time point versus
t = 0; n = 3–6).(Figures 4A and 4E) and prevented the fall in BAT and surface
body temperatures in Ucp1+/+ mice (Figures 4B and 4F). In
contrast, FGF21-mediated changes in glucose excursion were
abrogated, and changes in temperatures of the body surface
and BAT regions during glucose clearance were lost in both
vehicle and FGF21-treated Ucp1/ mice (Figures 4C–4F and
4H). These data suggest that FGF21may improve glucose clear-
ance by increasing UCP1-dependent thermogenesis.
DISCUSSION
Our study refines the role of UCP1-dependent thermogenesis
in the therapeutic actions of FGF21. We have shown that
FGF21 lowers body weight in the complete absence of
UCP1, consistent with other recent findings (Samms et al.,
2015; Ve´niant et al., 2015). Collectively, the three studies agree
that UCP1-dependent thermogenesis is not essential for the
anti-obesity actions of FGF21. However, these studies cannot
eliminate the possibility of increased UCP1-independent ther-
mogenesis and fuel wasting by FGF21, such as increased mito-
chondrial activity or biogenesis. It is interesting to note that
body weight-reducing effects of FGF21 therapy waned with
long-term and high-dose treatment. FGF21 resistance has
been reported in untreated diet-induced obese mice (Fisher
et al., 2010), and our data suggest that resistance to exoge-
nous FGF21 can be induced with chronic FGF21 therapy in
mice. Though our findings of similar waning of activity with
both human and mouse FGF21 suggest that an immunological
response is not responsible, the mechanisms behind the loss in
FGF21 efficacy should be investigated further, particularly with
a view to long-term FGF21 treatment in patients.Cell Reports 13, 1521–1527, NoOur data from three independent co-
horts of mice using two distinct methods
of FGF21 delivery clearly indicate that
FGF21 requires UCP1 to promote
glucose clearance following a bolus deliv-
ery. Comparable circulating basal and
glucose-stimulated insulin levels and
whole-body insulin sensitivity between
FGF21-treated Ucp1+/+ and Ucp1/mice suggest that FGF21 may utilize a UCP1-dependent and in-
sulin-independent mechanism to improve glucose intolerance.
In line with this notion, administration of an FGF21 analog to
streptozotocin (STZ)-induced insulin-deficient mice modestly
improves clearance of an oral glucose bolus compared to
vehicle, and these modest improvements correlate with in-
creased uptake of glucose tracer in BATs (Kim et al., 2015). It
is alsoworth noting that FGF21 improves long-term fasting blood
glucose levels in the absence of UCP1, yet the acute clearance
of a glucose load (post-prandial) by FGF21 requires UCP1.
These data suggest that FGF21-mediated clearance of glucose
in the fasting and post-prandial states may be mechanistically
distinct. In contrast to our findings, Ve´niant et al. (2015) reported
that Fc-FGF21 similarly improves glucose tolerance in both
Ucp1 knockout and heterozygous mice. Although we tested
the efficacy of FGF21 in mice that were obese, glucose intol-
erant, and insulin resistant, mice studied by Ve´niant et al.
(2015) were lean and presumably metabolically normal. Thus,
there may be differences in mechanisms behind the improved
glucose tolerance in lean and obese mice by FGF21. In addition,
differences in FGF21 levels achieved in the circulation (unre-
ported by Ve´niant et al., 2015) could potentially explain the
different observations, since FGF21 may activate alternate
UCP1-independent routes of glucose disposal if a higher level
of FGF21 is achieved in the circulation.
Here, we provide evidence that FGF21 may increase UCP1-
dependent thermogenesis during a glucose excursion. Tempera-
tures at the body surface and BAT vicinity fell gradually during a
glucose load in vehicle Ucp1+/+ (untreated and obese) mice,
correlating with the glucose excursion. These findings suggest
that maintaining stable BAT temperature through thermogenesisvember 24, 2015 ª2015 The Authors 1525
Figure 4. FGF21 Improves Blood Glucose Excursion and Prevents the Fall in Temperature of Body Surface and BAT
(A–F) In vehicle or FGF21-treatedUcp1+/+ (closed circles) andUcp1/mice (open circles), an OGTT was performed on day 35. Before and after glucose gavage,
blood glucose levels were measured to determine the change (D) in blood glucose from time 0 (A and C), and the AUC was calculated (E). Basal absolute blood
glucose levels were as follows: 11.0 ± 0.7 mM, Ucp1+/+ vehicle mice; 8.2 ± 0.9 mM, Ucp1+/+ FGF21 mice; 10.1 ± 0.9 mM, Ucp1/ vehicle mice; and 7.1 ±
0.2 mM, Ucp1/ FGF21 mice. Brown adipose tissue (BAT) temperatures (B and D) were approximated during OGTT with implantation of temperature tran-
sponders in the interscapular region, and the change (D) in BAT temperature at 20 min from time 0 was calculated (F).
(G andH) Infrared thermal images were taken during OGTT tomeasure temperature of body surface and representative images are shown. Thesemice are cohort
2 from Figures 2I–2K and S3. Line graphs (A–D) and bar graphs (E and F) are mean ± SEM and circles in bar graphs are individual mice. Statistical analysis was
performed by two-way ANOVA (#p < 0.05 vehicle versus FGF21 and *p < 0.05 indicated time point versus t = 0) for line graphs and Fisher’s least significant
difference (LSD) test (*p < 0.05; NS, not significant) for bar graphs (n = 4–6).may be an important physiological aspect of normal glucose
clearance and that defective BAT thermogenesis may contribute
to glucose intolerance. In line with this notion of defective
thermogenesis in obesity, BATactivity (asmeasuredby8F-fluoro-
deoxyglucose positron-emission tomography and computed
tomography) was observed to be significantly reduced in over-
weight and obese humans compared to lean controls during
cold exposure (van Marken Lichtenbelt et al., 2009), and active
BATdetectionwas lower in obese humanscompared to lean con-
trols (Cypess et al., 2009). Although the precise mechanism by
which BAT activity is defective in obesity is unknown, our data
demonstrate that FGF21 prevents the fall in temperatures of the
body surface and BAT while improving glucose clearance in
mice. Interestingly, in Ucp1/ mice, there were no differences
in temperatures at the body surface and BAT vicinity during
glucose excursion or differences between vehicle and FGF21-
treated mice during a glucose load. These data suggest that
FGF21 may improve glucose clearance by increasing BAT
temperature, likely involving UCP1-dependent thermogenesis.
Additionally, our data provide evidence that genetic or pharmaco-
logical induction of UCP1 in BAT, as in FGF21 therapy, may be1526 Cell Reports 13, 1521–1527, November 24, 2015 ª2015 The Aubeneficial to improve glucose intolerance. In conclusion, although
UCP1 recently was dismissed as being dispensable for FGF21-
mediated improvements in glucose metabolism, our study indi-
cates that UCP1 is required for FGF21-mediated improvements
in glucose tolerance, a key component of glucose homeostasis.
EXPERIMENTAL PROCEDURES
Study Approval
All experiments were approved by the University of British Columbia Animal
Care Committee and performed in accordance with the Canadian Council
on Animal Care guidelines.
Animals
Male Ucp1+/ mice (stock 000664) were obtained from the Jackson Labora-
tory and bred to generate Ucp1+/+ and Ucp1/ mice. Mice were housed at
29C–30C during the study except during metabolic tests (explained below).
See the Supplemental Experimental Procedures for more information on hous-
ing conditions and HFD and LFD feeding.
Hydrodynamic Human or Mouse Fgf21 Delivery
See the Supplemental Experimental Procedures for information on the gener-
ation of plasmids encoding the human or mouse Fgf21 for hydrodynamicthors
delivery. For hydrodynamic plasmid delivery, 2.0–2.5 ml saline solution (equiv-
alent to 8%–9% lean mass) containing 5 mg plasmid DNA was infused intra-
venously (i.v.) via tail vein over 5–8 s.
Metabolic Measurements
Blood glucose was sampled from the saphenous vein and measured using a
OneTouch Ultra Glucometer (LifeScan). For glucose tolerance and insulin
tolerance tests, mice were fasted for 4 hr at 21C–22C for acclimatization
to standard housing temperatures, given either an oral gavage or an i.p. injec-
tion of 2.0 g/kg 50% dextrose (Fisher Scientific) or given an i.p. injection of
0.4 U/kg insulin (Novolin ge Toronto; Novo Nordisk), and then blood glucose
levels were measured while animals were kept at 21C–22C. See the Supple-
mental Experimental Procedures for information on plasma analyte measure-
ments, assessment of body composition, and assessment of BAT and body
surface temperatures.
Statistics
The groups compared and the specific statistical analyses performed are out-
lined in the figure legends. Statistical analysis was performed using GraphPad
Prism 6.05 and statistical significance was set at p < 0.05.
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